Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -3.52% | -4.48% | +33.33% |
23/04 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
10/04 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Sales 2024 * | 72T 59.79L | Sales 2025 * | 72T 59.79L | Capitalization | 54.6L 45Cr |
---|---|---|---|---|---|
Net income 2024 * | -40L -33Cr | Net income 2025 * | -80L -66Cr | EV / Sales 2024 * | 75.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 75.8 x |
P/E ratio 2024 * |
-3.43
x | P/E ratio 2025 * |
-2.74
x | Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.83% |
1 day | -3.52% | ||
1 week | -4.48% | ||
Current month | +4.48% | ||
1 month | +3.78% | ||
3 months | +20.75% | ||
6 months | +10.98% | ||
Current year | +33.33% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13/10/13 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 27/22/27 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13/10/13 |
Wayne Linsley
BRD | Director/Board Member | 67 | 16/20/16 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
24/24/24 | 1.92 | -3.52% | 56,556 |
23/24/23 | 1.99 | -13.48% | 239,980 |
22/24/22 | 2.3 | +5.50% | 179,798 |
21/24/21 | 2.18 | +7.39% | 809,986 |
20/24/20 | 2.03 | +1.00% | 64,613 |
Delayed Quote Nasdaq, May 25, 2024 at 02:00 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.33% | 54.6L | |
-1.66% | 9TCr | |
-1.18% | 3.92TCr | |
-15.83% | 3.17TCr | |
+62.86% | 2.65TCr | |
-21.68% | 1.43TCr | |
-8.73% | 1.29TCr | |
-15.05% | 1.12TCr | |
-45.69% | 1.1TCr | |
+4.94% | 894.43Cr |
- Stock Market
- Equities
- SILO Stock